Invion Ltd (ASX: IVX) Share Price and News

Key Statistics

About Invion

Invion is a pioneering life-sciences company leading the development of Photosoft™ technology for treating a wide range of cancers, as well as atherosclerosis and infectious diseases.

Photosoft™ is a novel Photodynamic Therapy (PDT) which uses a photosensitising compound and light to generate destructive reactive oxygen species (ROS) which kills cancer cells selectively and promotes an anti-cancer immune response. It has minimal side effects when compared to radiotherapy and chemotherapy with acceptable applications for diagnostic and therapeutic uses.

IVX has a long-standing partnership with licensor RMW Cho Group to develop Photosoft. This partnership has been expanded several times since its original iteration to cover development against further indications and eventual commercialisation in an increasing number of countries in the Asia-Pacific and North American markets. Under the current iteration of the deal, IVX will have access to markets with more than 3.0bn people once commercialisation is achieved.

Invion Company History

IVX has been developing Photosoft™ since 2017. The company has broadened its operational and developmental reach across Asia and Oceania through strategic partnerships and licensing agreements. Ongoing development and the strategic patenting of its technology highlight Invion's commitment to innovation and the protection of its intellectual property. These efforts strengthen its market position and are likely to boost investor confidence in its long-term potential and success within the biotechnology and pharmaceutical industries.

IVX was working on several compounds, but by 2020 was focused on just two which were codenamed IVXP02 and IVX-P03. The latter of these compounds was unveiled in September 2019. COVID19 delayed plans for clinical trials using IVX-P03, but also gave IVX an opportunity to create a significant number of new compounds, from which arose multiple new patent filings. By April 2021, the company had reached what it considered to be a clinical candidate with INV043. In May 2021, IVX reported early work showing that INV043 was much more potent than IVX-P03. Specifically, it had ~50 times greater phototoxicity than IVX-P03 and ~600 times greater than the widely used photosensitiser Talaporfin sodium.

Invion has made substantial progress in FY24. In particular, it successfully manufactured the INV043 drug substance under a Good Manufacturing Practice (GMP) compliant manufacturing process, unveiled a study that showed that INV043 (in combination with an immune checkpoint inhibitor therapy) was effective in 80% of subjects in the trial, and signed a collaboration agreement with Korean company Dr.inB to develop Photosoft™ for the treatment of Human Papaloma Virus (HPV).

Future Outlook of Invion (ASX: IVX)

Invion's future looks promising due to its clinical results achieved to date. It is set to enter Phase 1b/2 in the next couple of years. However, it is reliant on external funding for the foreseeable future and with only 2.5 quarters cash left as at 31 March 2024, it will likely need a capital raising soon.

Is Invion (ASX: IVX) a Good Stock to Buy?

Not at this stage. We think the stock is too illiquid to consider right now.

Our Stock Analysis

Sorry, we couldn't find any posts. Please try a different search.

Frequently Asked Questions

Invion is at the forefront with a method called PhotoDynamic Therapy (PDT) for cancer treatment. They use a special agent, IVX-PDT, drawn from their Photosoft™ Technology, aiming to treat cancer more effectively with fewer side effects.

Related Companies